Evolution Research Group snaps up Finger Lakes Clinical Research for CNS trials

A MRI scan consistent with the clinical diagnosis of ALS
(By Frank Gaillard [GFDL 1.3 (www.gnu.org/licenses/fdl-1.3.html), GFDL 1.3 (www.gnu.org/licenses/fdl-1.3.html) or CC BY-SA 3.0 (http://creativecommons.org/licenses/by-sa/3.0)], via Wikimedia Commons)

Looking to boost its offerings in central nervous system trials, Evolution Research Group has bought up New York-based Finger Lakes Clinical Research.

The deal, financial details of which are not being disclosed, sees ERG take over FLCR, a clinical research facility that focuses on central nervous system trials and caters to a number of biopharmas.

The facility has worked on a host of CNS research including anxiety disorders, ADHD, depression, bipolar disorder, schizophrenia and other mental illnesses. It was founded back in 2002.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

This dovetails with ERG’s work, which also specializes in CNS disorders including Alzheimer’s, memory loss, migraine and other areas, as well as obesity, liver and kidney diseases.  

Lori Wright, CEO of ERG, said: “The addition of FLCR expands ERG's geographic capabilities in both adult and pediatric outpatient trials and further enhances ERG's growing service offerings to our clients."

Michael Farah, chairman of ERG and Partner at Linden Capital Partners (which backs the company), added: “FLCR expands ERG's footprint in growing psychiatric therapeutic areas and provides additional diversification which will allow us to further service our world-wide clients to develop important new therapies.”

Suggested Articles

Galapagos is selling off its contract research organization Fidelta for $37 million to Polish life science company Selvita.

Decentralized study company Medable has raised a large $91 million funding round as it continues to ramp up the deals in 2020.

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.